First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
TRAXV
Get informed when a big investor buys or sells
+ FollowMarket Cap$782.2M
Close$
Share Statistics
| Market cap | $782.20 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $- |
| Beta | 0 |
| Outstanding Shares | - |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -16.13 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
CEO: Daniel R. Faga First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology firm focused on advancing antibody therapies. These innovative treatments are designed to modulate immune system pathways that contribute to autoimmune and inflammatory...